Skip to main content
US EQUITIES PRE-MARKET CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
AB

ABBVStockAbbVie Inc.

New York Stock Exchange · Healthcare · US

$286.01+0.00% today
52-week $190.75 $302.93
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment ABBV's does — no target price to set, unlike a price alert.

Stable Ratio screen, 4 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-06
4 of 7 pass our financial screen — the standards disagree
🕌 Held by MNZL HTR non-permissible income 0.43%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🟡 BULLISH LEAN
The main driver: outperforming the market by 7.2%, RSI in healthy zone, Wall Street broadly bullish. More signals...
Scores: 3 bullish / 1 bearish
58
of 100
Setup confidence — system conviction, not win probabilityC

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

MOM · SCALP
Entry
$274.51
Stop
$271.76
Target
$280.01
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 5 timeframes bullish · 95.7% aligned
VWAPPrice below VWAP ($293.46)
VolumeRelative volume 2.6× the 20-day average
Momentum10-day rate of change -1.5%
Overall readBULLISH LEAN

AbbVie Inc. (ABBV) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
BUY
39 analysts
Institutional own.
77.5%
of shares
Momentum (10d)
-1.5%
rate of change
SMC grade
C · 58
95.7% aligned
🕌 MNZL
Held by real halal ETF(s)
0.43%
Non-permissible income — HTR, from filings (2025-12-31)
C · 58
SMC grade — 95.7% timeframe alignment
-1.5%
Rate of change (10d)
BUY
Wall Street consensus (39)
77.5%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to ABBV’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $520.7B as of 2026-11-17. At the 2026-11-18 close it is about $513.3B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 14.1% (13.9% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 2.1% (2.1% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 13.87% 30.00% Pass(16.1pp buffer)
Interest-bearing investments 2.07% 30.00% Pass(27.9pp buffer)
Non-permissible income 0.43% 5.00% Pass(4.6pp buffer)
Usmani Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 48.91% 33.00% Fail(15.9pp over)
Interest-bearing investments 7.30% 33.00% Pass(25.7pp buffer)
Non-liquid assets 83.56% at least 20.00% Pass(63.6pp above the floor)
Non-permissible income 0.43% 5.00% Pass(4.6pp buffer)
MSCI Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 48.91% 33.33% Fail(15.6pp over)
Cash + interest-bearing securities 7.30% 33.33% Pass(26.0pp buffer)
Accounts receivable 16.44% 33.33% Pass(16.9pp buffer)
Non-permissible income 0.43% 5.00% Pass(4.6pp buffer)
FTSE Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 48.91% 33.33% Fail(15.6pp over)
Cash + interest-bearing securities 7.30% 33.33% Pass(26.0pp buffer)
Accounts receivable 16.44% 50.00% Pass(33.6pp buffer)
Non-permissible income 0.43% 5.00% Pass(4.6pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 18.80% 33.00% Pass(14.2pp buffer)
Cash + interest-bearing securities 2.80% 33.00% Pass(30.2pp buffer)
Accounts receivable 3.52% 33.00% Pass(29.5pp buffer)
Non-permissible income 0.43% 5.00% Pass(4.6pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 20.50% 33.00% Pass(12.5pp buffer)
Cash + interest-bearing securities 3.06% 49.00% Pass(45.9pp buffer)
Accounts receivable 3.83% 49.00% Pass(45.2pp buffer)
Non-permissible income 0.43% 5.00% Pass(4.6pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 20.50% 33.33% Pass(12.8pp buffer)
Cash + interest-bearing securities 3.06% 33.33% Pass(30.3pp buffer)
Accounts receivable 6.89% 49.00% Pass(42.1pp buffer)
Non-permissible income 0.43% 5.00% Pass(4.6pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 4.6pts
Usmani (% of total assets)non permissible income ratio 4.6pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 4.6pts
Usmani (% of total assets)debt ratio 15.9pts
MSCI Islamic Index (% of total assets)debt ratio 15.6pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 15.6pts

The numbers the ratios are built from

Read from ABBV's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $61.2B 2025-12-31 Revenues
Interest-bearing debtShort and long-term borrowings $72.2B 2026-09-30 LongTermDebtAndCapitalLeaseObligations, ShortTermBorrowings
Cash and interest-bearing securitiesCash, equivalents and marketable securities $10.8B 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $147.7B 2026-09-30 Assets
Market capDenominator for AAOIFI $520.7B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $342.5B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $372.7B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $266.0M 2025-12-31 InvestmentIncomeInterestAndDividend

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2025-12-31. Screened 2026-11-17.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$147.7B
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$72.2B
    LongTermDebtAndCapitalLeaseObligations, ShortTermBorrowings · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$10.8B
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · balance sheet as of 2026-09-30
  • Receivables$13.5B
    AccountsReceivableNetCurrent · balance sheet as of 2026-09-30
  • Revenue$61.2B
    Revenues · income statement as of 2025-12-31
  • Interest income (non-permissible)$266.0M
    InvestmentIncomeInterestAndDividend · income statement as of 2025-12-31
  • Market cap$520.7B
    Market-data quote at screen time, 2026-11-17 · not a filing figure, so no link

What changed, and when

Verdict history for ABBV. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for ABBV has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Revenue by business segment

Not disclosed by segment: the latest 10-K (fiscal year ended 2025-12-31) does not tag its revenue by product, service or business segment in its XBRL, so there is no split to show. None is estimated.

Source: 10-K filed 2026-02-20 (accession 0001551152-26-000008), read from its XBRL on SEC EDGAR.

What would change the status

The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-17.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (13.9% against a 30% line) would only fail if the market cap fell by 54%, to $240.8B. At the 2026-11-18 close it would read 14.1%.

AAOIFI's investments ratio (2.1% against a 30% line) would only fail if the market cap fell by 93%, to $35.9B. At the 2026-11-18 close it would read 2.1%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
LLYLilly(Eli) & Co $1.2T —
JNJJohnson & Johnson $658.0B —
MRKMerck & Co Inc $371.7B —
NVSNovartis AG - ADR $306.5B —
AZNAstrazeneca plc - ADR $252.0B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold ABBV

24 of the 157 funds whose filed holdings we currently hold own ABBV shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns ABBV.

Shariah funds
FundABBV in fundFund compliant by weight
SPUS SP Funds S&P 500 Sharia Industry Exclusions ETF 1.18% 79%
You may already own it

Widely held U.S. index funds. If you own one, you own ABBV through it. None of them is a Shariah fund; the last column is our look-through of each.

FundABBV in fundFund compliant by weight
VYM VANGUARD HIGH DIVIDEND YIELD INDEX FUND 1.80% 46%
SPY 0.69% 56%
VOO VANGUARD 500 INDEX FUND 0.69% 56%
SPYM State Street(R) SPDR(R) Portfolio S&P 500(R) ETF 0.69% 56%
IVV iShares Core S&P 500 ETF 0.69% 56%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.61% 54%
SCHB Schwab U.S. Broad Market ETF 0.61% 53%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.61% 54%
RSP Invesco S&P 500 Equal Weight ETF 0.22% 44%
IWF iShares Russell 1000 Growth ETF 0.11% 69%
Other funds
FundABBV in fundFund compliant by weight
NSEIX Nicholas Equity Income Fund, Inc. 2.06% 54%
GQGU GQG US Equity ETF 1.83% 28%
RCLIX T. Rowe Price U.S. Large-Cap Core Fund, Inc. 1.40% 59%
VYCIX VOYA CORPORATE LEADERS(R) 100 FUND 0.98% 46%
SFY SoFi Select 500 ETF 0.80% 61%
PBP Invesco S&P 500 BuyWrite ETF 0.70% 54%
SFGV Sequoia Global Value ETF 0.54% not computed
VTWAX VANGUARD TOTAL WORLD STOCK INDEX FUND 0.38% 50%
AVUS Avantis U.S. Equity ETF 0.35% 49%
VDSIX Victory Diversified Stock Fund 0.27% 54%
3 more funds
FundABBV in fundFund compliant by weight
VWNAX VANGUARD WINDSOR II FUND 0.17% 34%
FGKFX Fidelity Growth Company K6 Fund 0.14% 55%
AMTOX AB All Market Real Return Portfolio 0.02% 32%

Sorted by ABBV’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names ABBV once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding ABBV
InvestorFirmPositionWeightAs of
Ken Fisher Fisher Asset Management $2,633M 0.8% 2026-09-30
Ken Griffin Citadel Advisors $1,320M 0.1% 2026-09-30
Israel Englander Millennium Management $320M 0.1% 2026-09-30
Saturna Capital Amana Mutual Funds Trust $267M 3.1% 2026-09-30
David Shaw D. E. Shaw & Co. $245M 0.1% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $117M 0.2% 2026-09-30
Larry Robbins Glenview Capital Management $33M 0.5% 2026-09-30
Robert Bruce Bruce & Co. $32M 8.6% 2026-09-30
Joel Greenblatt Gotham Asset Management $32M 0.1% 2026-09-30
Torray Investment Partners Torray Investment Partners $22M 2.9% 2026-09-30
Mairs & Power Mairs & Power $11M 0.1% 2026-09-30
David Katz Matrix Asset Advisors $9M 0.7% 2026-09-30
Azzad Asset Management Azzad Asset Management $8M 0.7% 2026-09-30
Jeff Auxier Auxier Asset Management $8M 1.1% 2026-09-30
Steven Cohen Point72 Asset Management $7M 0.0% 2026-09-30
Mario Gabelli GAMCO Investors $4M 0.0% 2026-09-30
Thomas Russo Gardner Russo & Quinn $3M 0.0% 2026-09-30
Jefferies Jefferies Financial Group $3M 0.0% 2026-09-30
Dodge & Cox Dodge & Cox $3M 0.0% 2026-09-30
Jensen Investment Management Jensen Investment Management $2M 0.1% 2026-09-30
Sallie Krawcheck Ellevest $1M 0.1% 2026-09-30
Bill Nygren Harris Associates (Oakmark) $1M 0.0% 2026-09-30
Lee Ainslie Maverick Capital $0M 0.0% 2026-09-30
Jeremy Grantham GMO $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

295.03269.97244.91219.85194.792025-11-192026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
288.13
S2
289.57
S1
291.19
PIVOT
292.63
R1
294.25
R2
295.69
R3
297.31

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
250.64 – 278.04
±5.18% from 264.34, made 2026-09-26 · resolves 2026-10-03
STRONG BUY
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

SELL
19 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesBUY
7 buy · 0 neutral · 5 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)48.90NEUTRAL
Stochastic %K (14)22.60NEUTRAL
CCI (20)-50.03NEUTRAL
Williams %R (14)-77.40NEUTRAL
MACD (12,26,9)-1.19SELL
ROC (10)-2.99SELL
Momentum (10)-8.82SELL
EMA (10)291.59SELL
SMA (10)292.46SELL
EMA (20)289.20SELL
SMA (20)290.49SELL
EMA (30)285.77BUY
SMA (30)287.15SELL
EMA (50)279.07BUY
SMA (50)277.04BUY
EMA (100)265.53BUY
SMA (100)264.73BUY
EMA (200)246.06BUY
SMA (200)239.25BUY

About AbbVie Inc.

Healthcare · Drug Manufacturers - General

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

abbvie.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-10-07

MOM
Type · SCALP
274.51
Entry
271.76
Stop
280.01
Target
LOSS
Outcome · exit 271.76 (-1.00%)

Stop 271.76 Now 286.01 Target 280.01

Verdict

🟡 BULLISH LEAN

The main driver: outperforming the market by 7.2%, RSI in healthy zone, Wall Street broadly bullish. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert ABBV [level]` to catch the entry, or `!plan ABBV` to size small.

Scores: 3 bullish / 1 bearish

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 64
⏰ 4H BEARISH 50
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-1.5%
Rate of change (10d)
2.6×
Volume vs its 20-day average
4.25
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NEUTRAL   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

Key Statistics

From the nightly market snapshot, shown so the verdict sits beside the numbers it does not depend on.

Biotechnology
Sector · Biotechnology
$505.6B
Market cap
54
RSI
4/10
Risk score

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.